YinYYangTLiuY, et al. Association between hepatic steatosis with significant fibrosis and CAD severity in different glucose metabolic states: a CSCD-TCMplus study. Angiology, Published online November 12, 2025. doi:10.1177/00033197251382388.
2.
RinellaMELazarusJVRatziuV, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.
3.
MuzurovićERizzoMMikhailidisDP.Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients. J Diabetes Complications. 2022;36:108359.
4.
KokkorakisMMuzurovićEVolčanšekŠ, et al. Steatotic liver disease: pathophysiology and emerging pharmacotherapies. Pharmacol Rev. 2024;76:454-499.
5.
MuzurovićEMikhailidisDPMantzorosC.Commentary: from mice to men: in search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism. 2020;109:154305.
6.
BorozanSVujosevicSMikhailidisDPMuzurovicE.Metabolic dysfunction-associated steatohepatitis and cardiovascular disease prevention - is resmetirom useful?Curr Vasc Pharmacol. 2025;23:4-7.
7.
MuzurovićEMikhailidisDPMantzorosC.Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770.
8.
MuzurovićEPengCCBelangerMJSanoudouDMikhailidisDPMantzorosCS.Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79:1319-1326.
9.
MuzurovićEMaćešićMKavarićS.Liver fibrosis and atherosclerosis, a consequence of metabolic dysfunction-do they share a similar pathophysiological background?Angiology. 2025;76:717-719.
10.
MuzurovićEMVolčanšekŠTomšićKZ, et al. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease-current evidence. J Cardiovasc Pharmacol Ther. 2022;27:10742484221146371.
11.
MuzurovićETopićGTodorovićNRizzoMZečevićK.The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. J Diabetes Complications. 2025;39:109147.
12.
Volčanšek Š, JanežARizzoMMuzurovićE. Monitoring the liver as a part of the cardio-renal-metabolic continuum - what is cooking and burning with non-invasive tests and treatment options?J Diabetes Complications. 2024;38:108875.
13.
HuMYangJGaoB, et al. Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus. Diabetol Metab Syndr. 2025;17:10.
